ACTIONS:Antiarrhythmic drug with sodium channel blocking, and anti-sympathetic nervous system properties, resulting in negative dromotropic effect on the heart.Prolonged administration results in a lengthening of the cardiac action potential.Amiodarone possesses negative chronotropic effects slowing conduction and prolonging the refractory period. Amiodarone administration prolongs intranodal conduction and refractoriness of the atrioventricular node, but has no effect on the sinus node. Used in a wide variety of atrial and ventricular tachyarrhythmias and for rate control of rapid atrial arrhythmias in patients with impaired LV function.
INDICATIONS: Ventricular Fibrillation and Pulseless Ventricular Tachycardia.• Treatment of Polymorphic Ventricular Tachycardia and Wide ComplexTachycardia of uncertain etiology• Control of hemodynamically stable Ventricular Tachycardia whencardioversion is unsuccessful• Used as adjunct to cardioversion of SVT and PSVT• May be used for rate control in atrial fib and flutter when other therapies areineffective or contraindicated• Acceptable for termination of ectopic or multifocal atrial tachycardia with LeftVentricular dysfunction
CONTRAINDICATIONS:• Torsade de Pointes• Cardiogenic Shock• Hypotension
PRECAUTIONS:• May produce vasodilatation and hypotension, and negative inotropic effects• May prolong QT interval, DO NOT USE WITH OTHER DRUGS THAT PROLONG THE QT INTERVAL• Use with caution in renal failure, half-life can last up to 40 days
ADVERSE REACTIONS:• Hypotension• Headache• Bradycardia• AV conduction abnormalities• Flushing
DOSAGE:• Cardiac Arrest: 300 mg IV push, repeated in 3-5 minutes at 150 mgs if required.• Wide Complex Tachycardia (stable): 150mg in 100 ml D5W over 10 minutes• Pediatric dose in VF/pulseless VT is 5 mg / kg• Pediatric dose in perfusing supraventricular and ventricular arrhythmias is 5mg/ kg over 20-60 minutes ( max of 15 mg /kg / day ).
HOW SUPPLIED: 150 mg in a 3 ml vial